The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.79 — safe zoneOK
- Earnings-manipulation signal · Beneish M -0.99 — flag raised, worth a closer lookWatch
- Earnings quality 66/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as ACADIA PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Nuplazid$680.1M
- Daybue$391.4M
Leadership changes
From ACADIA PHARMACEUTICALS INC's own filings, the day they're filed.
- Elizabeth H. · Directors · departureeff. 2026-04-27
- Z. Thompson · Directors · departureeff. 2026-04-27
- Daniel B. Soland · Directors · departureeff. 2025-10-30
Latest filings
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-06
- 8-K · Company announcement2026-05-01
- DEF 14A · Annual proxy (pay & governance)2026-04-24
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ACADIA PHARMACEUTICALS INC, every answer cited🔒
- The Intelligence Brief — added when ACADIA PHARMACEUTICALS INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.